Instil Bio (TIL)
(Delayed Data from NSDQ)
$22.23 USD
-1.77 (-7.38%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.29 +0.06 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TIL 22.23 -1.77(-7.38%)
Will TIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TIL
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
TIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Other News for TIL
Instil Bio (TIL) Gains from Promising Clinical Trial Results
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying ...
Instil Bio to begin testing antibody therapy in solid tumors
12 Health Care Stocks Moving In Wednesday's Pre-Market Session